All financings
COMPANY TRANSACTIONS

Lexaria Bioscience Corp.

LEXXNasdaqBiotechnology

Deal details

1 transaction in the database

TRANSACTION REPORT · SEC DISCLOSURES

Deal notes

Not yet verifiedClosing confirmation

Closing has not been confirmed in the reviewed sources. This record does not establish that funding was received.

Gross proceeds$5.9M
Offering price$12.92
Discount to prior close8.7%
Warrant coverage—
Placement agent / underwriterH.C. Wainwright & Co.

Transaction overview

01

Lexaria Bioscience Corp. announced a $5.9M warrant exercise / inducement at $12.92 per warrant exercised. H.C. Wainwright & Co. acted as exclusive placement agent for the financing.

Financing type
Warrant Exercise / Inducement
Announcement date
Sep 8, 2026
Agreement date
Sep 7, 2026
Pricing date
—
Closing date
—
Filing date
Sep 9, 2026
Status
Priced
Market cap before announcement
$23.4M
Prior closing price
$14.15
Raise as % of market cap
25.2%

Market data · FMP

Historical market cap
$23,400,251
Market date
Sep 4, 2026
Closing price
$14.15
Latest reported shares outstanding
1,652,496
Latest reported float shares
1,602,575
Share-data date
Sep 30, 2026

Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 1, 2026.

Financial Modeling Prep ↗

Financing terms

02

Warrant exercise / inducement

Warrants exercised
453,969
Original exercise price
Varies by original cohort
Exercise price paid
$12.92
Cash proceeds
$5.9M

Original warrant cohorts

February 2024

Originally issued
Feb 16, 2024
Original exercise price
$32.78
Exercised from this cohort
—

October 2024

Originally issued
Oct 16, 2024
Original exercise price
$45.90
Exercised from this cohort
—

September 2025

Originally issued
Sep 29, 2025
Original exercise price
$20.55
Exercised from this cohort
—

December 2025

Originally issued
Dec 16, 2025
Original exercise price
$17.85
Exercised from this cohort
—

453,969 existing warrants in aggregate; allocation of exercised warrants among the four historical cohorts is not disclosed in this filing.

Series A investor warrants

Warrant shares
453,969
Cash exercise price
$12.67
Term
Five years from the Effective Date defined in the Inducement Letter; immediately exercisable.
Initial exercisability
—
Beneficial ownership limits
—

Series B investor warrants

Warrant shares
453,969
Cash exercise price
$12.67
Term
Eighteen months from the Effective Date defined in the Inducement Letter; immediately exercisable.
Initial exercisability
—
Beneficial ownership limits
—

Placement agent warrants

Warrant shares
15,889
Cash exercise price
$16.15
Term
Five years from the Effective Date defined in the Letter Agreement, extended to the next Trading Day if necessary.
Initial exercisability
—
Beneficial ownership limits
—

Compensation warrants are excluded from investor warrant coverage.

Fees & transaction economics

03
Placement agent / underwriting fee
7%
Agent fee amount
$413,000
Management fee
—
Other offering expenses (estimated)
—
Net proceeds (estimated)
—
Net proceeds as % of gross
—

Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.

Transaction participants

04
Investor names: —

Source documents

05

SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.

8-K · Lexaria Bioscience Corp.SEC filing · Sep 9, 2026
Open source ↗
EX-10.1 · Lexaria Bioscience Corp.SEC filing · Sep 9, 2026
Open source ↗
EX-4.1 · Lexaria Bioscience Corp.SEC filing · Sep 9, 2026
Open source ↗
EX-4.2 · Lexaria Bioscience Corp.SEC filing · Sep 9, 2026
Open source ↗
EX-99.1 · Lexaria Bioscience Corp.SEC filing · Sep 9, 2026
Open source ↗
FMP historical market data · LEXXMarket data · Sep 4, 2026
Open source ↗
SEC deal terms · FMP market data where available · Initial research sample, not complete market coverage. AI-assisted source review; original evidence is available in each report. Names and tickers reflect the transaction date. A dash (—) means the value is unavailable.